Moderna announced yesterday its expansion plans in the Asia Pacific region with four new subsidiaries to be established in Malaysia, Taiwan, Singapore and Hong Kong. The development signifies Moderna’s commitment to Asia and will provide support to the region in the delivery of its vaccines and therapeutics.
The Asia-Pacific region represents an integral part of Modern’s business, with established subsidiaries in Japan, South Korea and Australia the announcement stated and comes at a time when the company is in the midst of scaling up its manufacturing and distribution of its COVID-19 vaccine.
Stéphane Bancel, CEO of Moderna commented, “2021 was a year of impact for Moderna, and I am so proud to see continued growth in 2022 as we expand our presence in Asia. After a decade of pioneering the development of our mRNA platform, we were ready to play a critical role in combating the COVID-19 pandemic globally. With the addition of four subsidiaries in Asia, we look forward to new opportunities to leverage our platform to help solve health challenges in the Asia-Pacific region.”
As such, the company is looking to hire 1,000 staff to drive its expansion in the region. The Hong Kong office will also help to deliver vaccines and therapeutics in the city and Macau as well as pioneering the development of new vaccines in Asia according to Bancel.
Moderna currently has a presence in twelve markets globally. Regulators have approved Moderna’s COVID-19 vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel. In 2021, 807 million doses of their vaccine were shipped globally with approximately 25% of those going to low- and middle-income markets.
Paul Arkwright
Publisher
